This is the authors' abstract. We don't add key points for this paper.
Purpose Gram-positive bacteria are frequently resistant to empirical beta-lactams in febrile neutropenic patients with cancer. As microbiology and antibiotic susceptibility changes, we reevaluated the risk factors for resistant Gram-positive bacteremia in febrile neutropenic patients with cancer.Methods Episodes of bacteremic febrile neutropenia in Seoul National University Hospital from July 2019 to June 2022 were reviewed. Resistant Gram-positive bacteria were defined as a pathogen susceptible only to glycopeptide or linezolid in vitro (e.g., methicillin-resistant staphylococci, penicillin-resistant viridans streptococci, and ampicillin-resistant enterococci). Episodes were compared to identify independent risk factors for resistant Gram-positive bacteremia.Results Of 225 episodes, 78 (34.7%) involved resistant Gram-positive bacteremia. Multivariate analysis revealed that breakthrough bacteremia while being administered antibiotics (adjusted odds ratio [aOR], 8.006; 95% confidence interval [95% CI], 3.532–18.151; P < 0.001), catheter-related infection (aOR 4.425, 95% CI 1.469‒13.331; P = 0.008), and skin or soft tissue infection (aOR 24.421, 95% CI 2.043‒291.862; P = 0.012) were associated with resistant Gram-positive bacteremia. Chronic liver disease (aOR 0.245, 95% CI 0.063‒0.973; P = 0.046) and hypotension at bacteremia (aOR 0.462, 95% CI 0.219‒0.972; P = 0.042) were inversely associated with resistant Gram-positive bacteremia.Conclusion Resistant Gram-positive bacteria should be considered in breakthrough bacteremia, catheter-related infection, and skin or soft tissue infection in febrile neutropenic patients with cancer.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2023) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: